Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill
Clinical Study of Yangxue Qingnao Pill in the Treatment of Mild Vascular Cognitive Impairment Without Dementia (VCIND)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100098
- Peking University Third Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Over 50 years old, under 85 years old, male and female, including 50 and 85 years old;
- The patients agreed to participate in the trial and signed the informed consent.
The diagnostic criteria for vascular cognitive impairment without dementia are as follows:
- There are risk factors of cerebrovascular disease or the existence of cerebrovascular disease;
- The development of cognitive impairment was fluctuating;
- Mild memory impairment or retention;
- There is a causal relationship between cerebrovascular disease and cognitive impairment, and other diseases are excluded;
- The activities of daily living remained normal;
- According to the diagnostic criteria of mild cognitive impairment (MCI) developed by Xiao Shifu, the subjects' MMSE score was less than or equal to 26
Exclusion Criteria:
- The researchers considered that it was not suitable to be included in the study;
- Known liver diseases of clinical significance, which may hinder patients from completing the test, and / or total bilirubin, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase are 1.5 times higher than the upper limit of normal value;
- The patients with known clinically significant kidney disease may be prevented from completing the test, and / or the serum creatinine is higher than the normal range in the laboratory, and / or the blood urea nitrogen is 1.5 times higher than the normal range;
- He had a history of acute cerebrovascular disease within 3 months;
- At present, there is active epilepsy;
- History of mental illness;
- Peptic ulcer and gastrointestinal bleeding;
- Any of the tested drugs was taken within 28 days before medication, which may cause cognitive changes and important organ damage.
- Accompanied by unstable blood system and immune system diseases, is not in clinical remission.
- Malignant tumor or intracranial tumor is known;
- Those who had surgery within three months or had a history of trauma.
- There are other advanced, serious or unstable diseases, which affect the evaluation of its efficacy and safety;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
OTHER: blank control group
|
There were 20 cases in the blank control group.Outpatient consultation at any time was prescribed.
|
|
EXPERIMENTAL: treatment group(Yangxue Qingnao pill)
|
The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months
|
|
ACTIVE_COMPARATOR: control group(hidezhen)
|
The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Montreal Cognitive Assessment Scale (MoCA)
Time Frame: at 6th month
|
Level of cognition,ranging from 0-30 points, the higher score means better outcome
|
at 6th month
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- M2017154
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.